John Moore considers his move into the healthcare equity capital markets (ECM) team at Morgan Stanley in 2000 as a decisive moment in his career. It coincided with the sequencing of the human genome, which led to a substantial increase in equity-raising among biotechnology companies making use of genomic science for medical treatments.
Mr Moore immersed himself in understanding biological research and healthcare science during a period of intense initial public offering (IPO) activity. As the bank’s head of Americas ECM since 2010, he retains that attention to innovation as a key source of activity for his division. Morgan Stanley holds an annual 'Next Generation' IPO conference that brings together investors and private companies with IPO prospects.
